Trial
NCT06424717
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Urothelial Carcinoma
Intervention
Avelumab
Why stopped
Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No subjects were enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-27